[November 17, 2014]

Research and Markets: Global Radiopharmaceuticals/Nuclear Medicine Market Analysis - Trends & Forecast to 2020

Research and Markets (http://www.researchandmarkets.com/research/gzdwtm/global) has announced the addition of the "Global Radiopharmaceuticals/Nuclear Medicine Market Analysis - Trends & Forecast to 2020" report to their offering.

The nuclear medicine market by indication is segmented as oncology, cardiology, inflammation, nephrology, neurology, lymphology, thyroid glands, and gastro intestinal. Cardiology holds the largest share in 2013 in SPECT nuclear medicine market whereas nephrology is the fastest growing application of this segment. Increasing incidence of cardiac ailments, aging population, and preference for non invasive diagnostic procedures are driving the market for cardiology segment.

Oncology contributes to the largest share of around $1 billion and is also the fastest growing segment in PET market with a CAGR of more than 7%. Nephrology is the fastest growing segment in the therapeutics. Increase in therapeutic application, public awareness, use of hybrid imaging, technological advancements, cyclotron production of radiopharmaceutical, efficient diagnosis and treatments, emerging radioisotopes and replacement of traditional equipment are factors or opportunities expected to drive the nuclear medicine market. However, stringent regulatory issues, supply shortage, radio toxicity, high cost and huge investment are factors hindering the market growth during the forecasted period.

North America holds the largest share for nuclear medicine market, followed by Europe. The U.S. market is highly supported by the Mo-99 production of NRU reactor (Canada) and ongoing researches in different clinical institutes such as National Cancer Institute, Avid Radiopharmaceuticals and so on. Besides developed markets, the Asia-Pacific region is expected to show a remarkable growth in the coming years. Asia-Pacific (APAC) and Rest of the World are poised to grow at a CAGR of more than 6% and 8% respectively by 2020. This region growth is attributed to aging population, rise in public awareness. Countries like China, India, Australia, and Brazil will be major contributors to the growth of the market.

Reasons to Buy:

• Nuclear medicine/Radiopharmaceuticals usage and demand by various end-users across the globe
• Emerging isotopes as well as alternative isotopes for use both in the SPECT and PET segments
• Emerging applications in Nuclear Medicine
• Regulations and Reimbursement scenario
• Stable isotopes study being a value addition
• Competitive landscaping and major player profiles

Key Topics Covered:

1. Summary

2. Introduction

3. Market Overview

4. Global Radiopharmaceutical market, by End-User

5. Global Radiopharmaceutical market, by Application

6. Stable Isotopes

7. Geographic Analysis

8. Competitors Landscape

9. Major Company Profiles

- CIL

- Cardinal Health, Inc.

- GE Healthcare

- IBA Group

- Isotec, Inc. (Sigma-Aldrich)

- Lantheus Medical Imaging, Inc.

- Mallinckrodt Plc

- NTP Radioisotopes

- Nordion Inc

- Taiyo Nippon Sanso Corporation

For more information visit http://www.researchandmarkets.com/research/gzdwtm/global

[ Back To TMCnet.com's Homepage ]